Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer
Cantex Pharmaceuticals announced the publication in the peer-reviewed journal, npj Breast Cancer, reporting results from in vitro and in vivo models for triple-negative breast cancer showing suppression of metastasis and tumor progression by RAGE inhibition. Cantex’s azeliragon is a RAGE inhibitor that is orally administered and taken once daily....